<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Euthyroid hyperthyroxinemia and hypothyroxinemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Euthyroid hyperthyroxinemia and hypothyroxinemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Euthyroid hyperthyroxinemia and hypothyroxinemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Many conditions result in increases or decreases in serum total thyroxine (T4) and triiodothyronine (T3) concentrations, associated with normal thyroid-stimulating hormone (TSH) concentrations and no symptoms or signs of thyroid dysfunction. This constellation of laboratory values has been referred to as euthyroid hyperthyroxinemia and hypothyroxinemia, respectively. The free T4 should be normal, but many assays will report slightly abnormal values; for example, the free T4 index and many direct free T4 assays report high values in familial dysalbuminemic hyperthyroxinemia (FDH).</p><p>In the past, these conditions presented a diagnostic challenge, and many of the patients with them were inappropriately treated for thyroid disease. Today, when most clinicians measure serum TSH as a screening test for thyroid function, a normal serum TSH value is usually not followed by measurement of a total serum T4. With the use of sensitive serum TSH assays and automated "direct" free T4 assays, euthyroid hyper- or hypothyroxinemia frequently remains undetected, with no harm to the patient.</p><p>However, the detection of a normal serum TSH concentration associated with a high or low serum T4 concentration, and sometimes free T4 concentration, should immediately alert the clinician to search for one of the causes of euthyroid hyper- or hypothyroxinemia, especially if the patient has no symptoms or signs of either hyper- or hypothyroidism.</p><p>This topic will review these conditions. Individual thyroid function tests are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EUTHYROID HYPERTHYROXINEMIA DUE TO BINDING PROTEIN ABNORMALITIES</span><span class="headingEndMark"> — </span>Both T4 and T3 circulate in blood bound to one of three binding proteins:</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroxine-binding globulin (TBG)</p><p class="bulletIndent1"><span class="glyph">●</span>Transthyretin (TTR; thyroxine-binding prealbumin [TBPA])</p><p class="bulletIndent1"><span class="glyph">●</span>Albumin</p><p></p><p>Approximately 99.97 percent of circulating T4 and 99.7 percent of circulating T3 are bound to these proteins. T4 binding is distributed as follows: TBG, 75 percent; TTR, 15 percent; and albumin, 10 percent. In comparison, T3 is less avidly bound to TBG and TTR.</p><p>Serum total T4 or T3 assays measure both bound and free (unbound) hormone. As a result, factors that alter binding protein concentrations can have profound effects on serum total T4 (and T3) concentrations even though serum free T4 (and T3) concentrations do not change and the patient is euthyroid.</p><p class="headingAnchor" id="H3"><span class="h2">TBG excess</span><span class="headingEndMark"> — </span>Thyroxine-binding globulin (TBG) excess is the most common binding protein abnormality. There are several major causes of this disorder:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary – Hereditary TBG excess is an X-linked dominant disorder characterized by increased synthesis of TBG [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estrogens – Estrogens increase the glycosylation of TBG, which slows its clearance, thereby increasing serum TBG concentrations [<a href="#rid3">3</a>]. Thus, serum TBG (and total T4 and T3) concentrations are increased substantially (25 to 50 percent) in pregnant women [<a href="#rid4">4</a>], women receiving an oral contraceptive [<a href="#rid5">5</a>], postmenopausal women receiving estrogen therapy [<a href="#rid6">6</a>], and patients with estrogen-secreting tumors, and serum TBG concentrations are increased slightly (10 to 25 percent) in women receiving <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid7">7</a>] and <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis – Patients with acute or subacute hepatitis, even those with minimal elevations in serum aminotransferase concentrations, have increased serum TBG concentrations [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs – Several drugs raise serum TBG concentrations, including <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [<a href="#rid11">11</a>], <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">perphenazine</a>, clofibrate [<a href="#rid12">12</a>], heroin, and <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute intermittent porphyria – Acute intermittent porphyria may be associated with increased serum TBG concentrations, via an uncertain mechanism [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The T3-resin uptake test was designed in part to detect abnormalities in serum TBG (see  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Serum free T4 and T3'</a>). This test measures the number of unoccupied T4-binding sites in serum. It is performed by incubating the patient's serum with radiolabeled T3 and subsequently adding a resin (or other binder such as talc or dextran-coated charcoal) to bind any radiolabeled T3 not bound to serum proteins  (<a class="graphic graphic_figure graphicRef72068" href="/z/d/graphic/72068.html" rel="external">figure 1</a>). In states of TBG excess, more radiolabeled T3 binds to TBG and less to the resin, resulting in a low T3-resin uptake  (<a class="graphic graphic_figure graphicRef72712" href="/z/d/graphic/72712.html" rel="external">figure 2</a>).</p><p>The value in normal subjects is usually normalized to 1 (range 0.83 to 1.16). The thyroid hormone-binding ratio (THBR) or index (THBI) is the ratio of the patient's T3-resin uptake value to the mean of the values in normal subjects. The serum free T4 index, which has no units, is calculated by multiplying the serum total T4 value by the binding ratio:</p><div class="formulaContainer"><div class="formula"><p>  Serum free T4 index  =  serum total T4  x  THBR</p></div></div><p>The presence of TBG excess is suggested by a low THBR in a patient with an elevated serum total T4 (or T3) concentration. In a pregnant woman, for example, the serum total T4 concentration might be 14 mcg/dL (180 nmol/L), but the THBR might be 0.68. The serum free T4 index would be normal (9.5 [14 x 0.68]).</p><p>These changes are reversed in patients with TBG deficiency (see <a class="local">'TBG deficiency'</a> below). In these patients, little radiolabeled T3 binds to TBG and most binds to the resin. The net effect is that the THBR is high, leading to a normal serum free T4 index even though the serum total T4 concentration is low  (<a class="graphic graphic_figure graphicRef65021" href="/z/d/graphic/65021.html" rel="external">figure 3</a>).</p><p>In contrast, the T3-resin uptake and therefore the serum free T4 index are high and low, respectively, in hyperthyroidism and hypothyroidism.</p><p>The changes in T3-resin uptake in TBG excess and deficiency and in hyperthyroidism and hypothyroidism can be summarized as follows.</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism – High serum total T4, high T3-resin uptake or THBR, high serum free T4 index</p><p class="bulletIndent1"><span class="glyph">●</span>TBG excess – High serum total T4, low T3-resin uptake or THBR, normal serum free T4 index</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism – Low serum total T4, low T3-resin uptake or THBR, low serum free T4 index</p><p class="bulletIndent1"><span class="glyph">●</span>TBG deficiency – Low serum total T4, high T3-resin uptake or THBR, normal serum free T4 index</p><p></p><p>At extremes of TBG excess or deficiency, the serum free T4 index may not be normal. However, the correct diagnosis can be established by demonstrating that the patient has a normal serum TSH concentration. In addition, serum TBG can be measured directly by radioimmunoassay, although this is rarely necessary.</p><p>In theory, direct free T4 assays should not be affected by changes in TBG. In practice, however, many automated free T4 assays perform poorly, especially in pregnancy and nonthyroidal illness, because they are adversely affected by the lower levels of albumin seen in pregnancy and nonthyroidal illness. Even though free T4 index measurements are normal in the second and third trimester, automated free T4 assays frequently give low values, and some kit manufacturers attempt to compensate for the poor performance of their assay by offering adjusted lower normal ranges during the second and third trimester [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Trimester-specific reference ranges'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Familial dysalbuminemic hyperthyroxinemia</span><span class="headingEndMark"> — </span>Familial dysalbuminemic hyperthyroxinemia (FDH) is a genetic disorder, most often occurring in patients of Hispanic ethnicity, in whom it occurs in perhaps 0.2 percent [<a href="#rid1">1,16</a>]. It is characterized by production of mutant albumin molecules that have a low affinity but high capacity for T4, but not T3 [<a href="#rid17">17</a>]. Affected patients have high serum total T4 concentrations but are euthyroid and have normal serum TSH concentrations.</p><p>The increased binding of T4 in FDH results in a misleading T3-resin uptake because the radiolabeled T3 does not bind to the abnormal albumin but does bind normally to the resin and to other serum proteins  (<a class="graphic graphic_figure graphicRef53941" href="/z/d/graphic/53941.html" rel="external">figure 4</a>). The net effect is a high serum total T4 concentration and a normal THBR, so that the calculated serum free T4 index is high. Before sensitive serum TSH assays were available, these patients were commonly misdiagnosed as having hyperthyroidism and treated accordingly.</p><p>While, in theory, direct free T4 measurements should result in normal free T4 levels in FDH, in reality, most are adversely affected by changes in albumin concentration and give spuriously high values [<a href="#rid18">18,19</a>].</p><p>There is usually no need to pursue the diagnosis of FDH if the patient is clearly euthyroid and has a normal serum TSH concentration. However, the diagnosis can be established by performing a resin (or charcoal) uptake test using radiolabeled T4 rather than radiolabeled T3 [<a href="#rid17">17</a>]. Serum from patients with FDH binds more radiolabeled T4 than does serum from normal subjects, thereby documenting that serum T4 binding is increased. The diagnosis can also be established by electrophoresis of binding proteins in the presence of radiolabeled T4. Alternatively, serum T4 and free T4 index can be measured in the patient's relatives; the inheritance of FDH is autosomal dominant.</p><p>FDH can be diagnosed by assessing gene variants in the albumin (ALB) gene. R218H, R218P, R222I, and R218S variants have been described [<a href="#rid20">20</a>]. The clinical presentation of the R218P variant differed from the patients described above; serum T4 concentrations were 11- to 17-fold above the upper limit of normal (versus two- to threefold), and serum T3 concentrations were elevated up to twofold above the upper limit of normal in some family members [<a href="#rid21">21,22</a>]. This variant may also bind excess cortisol [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Abnormal TTR binding of T4</span><span class="headingEndMark"> — </span>This very rare disorder is due to production of an abnormal transthyretin (TTR) that, like the abnormal albumin in patients with FDH, binds T4 but not T3 [<a href="#rid1">1,24</a>]. It can be diagnosed by either electrophoresis or by using anti-TTR antibodies to immunoprecipitate the protein in the presence of radiolabeled T4 [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Anti-T4 immunoglobulins</span><span class="headingEndMark"> — </span>The presence of anti-T4 immunoglobulins, a rare finding, can cause spuriously high serum T4 concentrations when T4 is measured by radioimmunoassay, or low values in immunometric assays [<a href="#rid26">26,27</a>]. These immunoglobulins are antibodies that bind T4, but are distinct from antithyroglobulin (and antithyroid peroxidase) antibodies. Nonetheless, virtually all patients with these antibodies have autoimmune thyroid disease. Most patients have been euthyroid because enough serum T4 was unbound to maintain normal function at the tissue level.</p><p>These human anti-T4 antibodies cause spuriously high serum total T4 values in T4 radioimmunoassays because they bind radiolabeled T4, thereby competing with binding of radiolabeled T4 to the rabbit anti-T4 antibodies used in the assays, which then interferes with the competition between labeled and endogenous T4 binding  (<a class="graphic graphic_figure graphicRef75308" href="/z/d/graphic/75308.html" rel="external">figure 5</a>). On the other hand, the THBR is normal because most endogenous anti-T4 antibodies do not bind T3. Some, but not all, direct free T4 assays give spuriously high results in the presence of anti-T4 antibodies [<a href="#rid28">28</a>]. Human anti-T4 antibodies cause spuriously low values in immunometric assays by preventing the endogenous T4 from interacting with the signal antibody.</p><p>Anti-T4 antibodies can be detected by adding radiolabeled T4 to the patient's serum and precipitating the immunoglobulin fraction by the addition of polyethylene glycol [<a href="#rid25">25</a>]. Precipitation of radiolabeled T4 indicates the presence of anti-T4 immunoglobulins.</p><p>Anti-T3 immunoglobulins have also been described [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H8"><span class="h1">OTHER CAUSES OF EUTHYROID HYPERTHYROXINEMIA</span></p><p class="headingAnchor" id="H9"><span class="h2">Reduced thyroxine deiodination</span><span class="headingEndMark"> — </span>Several drugs inhibit extrathyroidal T4 deiodination to T3, including <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in high doses, and the iodinated radiographic contrast agents ipodate and iopanoic acid [<a href="#rid29">29-32</a>] (see  <a class="medical medical_review" href="/z/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>). Administration of these drugs may result in hyperthyroxinemia with normal serum TSH concentrations.</p><p class="headingAnchor" id="H1018590530"><span class="h2">Assay artifact</span><span class="headingEndMark"> — </span>Many competitive binding assays for T4 or free T4 utilize biotinylated antibodies and a streptavidin-biotin separation technique. Excess ingestion of <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a> competes with the biotinylated analogue and results in spuriously high T4 or free T4 (or T3 or free T3) values. Measurements should be repeated after ingestion of biotin is omitted for two days [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Other conditions</span><span class="headingEndMark"> — </span>Several other disorders can also cause euthyroid hyperthyroxinemia:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute psychosis, acting via an uncertain mechanism [<a href="#rid34">34,35</a>] (see  <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>). From 1 to 10 percent of patients hospitalized for acute psychosis have modestly elevated serum T4 concentrations [<a href="#rid35">35</a>]. The elevation is usually transient, but measurement of serum TSH is indicated because a few of these patients are actually hyperthyroid [<a href="#rid35">35</a>]. Still, among 12 acutely depressed patients, none had a low serum TSH concentration and seven had slightly elevated concentrations that were probably transient [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High altitude and amphetamines, presumably mediated by a central nervous system mechanism [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic hyponatremia may be associated with small increases in serum total T4 concentrations [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Generalized thyroid hormone resistance results in high serum T4 concentrations associated with normal or slightly high serum TSH concentrations. These patients may be euthyroid, or have clinical manifestations of hypothyroidism or even hyperthyroidism, because the receptor defect can vary in different organs. (See  <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">"Resistance to thyroid hormone and other defects in thyroid hormone action", section on 'Resistance to thyroid hormone beta (RTH-beta and nonTR-RTH)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate T4 replacement therapy (with normalization of serum TSH concentrations) results in serum T4 concentrations that are 1 to 2 mcg/dL (13 to 26 nmol/L) higher than in normal subjects [<a href="#rid40">40</a>].</p><p></p><p class="headingAnchor" id="H15669268"><span class="h1">EUTHYROID HYPERTRIIODOTHYRONINEMIA</span><span class="headingEndMark"> — </span>A variant of albumin with 40-fold increased affinity for T3 but only 1.5-fold increased affinity for T4 has been described in a Thai family: familial dysalbuminemic hypertriiodothyroninemia [<a href="#rid41">41</a>].</p><p>In one study, 12.4 percent (13 of 105) newly diagnosed multiple myeloma patients, mostly of the immunoglobulin G (IgG) type, had hypertriiodothyroninemia that resolved with anti-myeloma therapy [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H11"><span class="h1">EUTHYROID HYPOTHYROXINEMIA DUE TO BINDING PROTEIN ABNORMALITIES</span><span class="headingEndMark"> — </span>Changes in the opposite direction from those described above can cause euthyroid hypothyroxinemia.</p><p class="headingAnchor" id="H12"><span class="h2">TBG deficiency</span><span class="headingEndMark"> — </span>Thyroxine-binding globulin (TBG) deficiency occurs in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary – Hereditary TBG deficiency is an X-linked recessive disorder [<a href="#rid1">1,2,43</a>]. The underlying cause is a mutation in one of the first four exons of the TBG gene [<a href="#rid44">44</a>]. In one family, however, low serum TBG concentrations were autosomally transmitted by an unknown mechanism; the patients' TBG gene was normal [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hormonal abnormalities – Androgens (high doses) reduce serum TBG concentrations and can result in a reduction in T4 requirement in hypothyroid patients [<a href="#rid46">46</a>]. Other hormonal causes of low serum TBG concentrations include glucocorticoid administration [<a href="#rid47">47</a>], Cushing syndrome, and acromegaly [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotic syndrome – Urinary loss of TBG in patients with the nephrotic syndrome can result in hypothyroxinemia. Most of the patients are euthyroid, but hypothyroidism can occur in those with poor thyroid reserve or in hypothyroid patients taking T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/3104.html" rel="external">"Endocrine dysfunction in the nephrotic syndrome", section on 'Thyroid function'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs – L-asparaginase [<a href="#rid50">50</a>], <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> [<a href="#rid51">51</a>], and <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">niacin</a> [<a href="#rid52">52</a>] all lower serum TBG concentrations, presumably by decreasing TBG production.</p><p></p><p>Starvation and poor nutrition can cause reductions in both serum TBG and albumin concentrations. (See  <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Displacement of T4 from binding proteins</span><span class="headingEndMark"> — </span>Several drugs, including: salicylates [<a href="#rid53">53</a>], <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a> [<a href="#rid54">54</a>], high doses of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> (especially in patients with renal failure) [<a href="#rid55">55</a>], and some nonsteroidal antiinflammatory drugs (fenclofenac and <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">mefenamic acid</a>) inhibit the binding of T4 to TBG. As a result, serum total T4 concentrations fall, but serum free T4 concentrations are normal.</p><p>Heparin can result in spuriously low serum T4 concentrations. It does so by activating lipoprotein lipase, thereby generating free fatty acids that inhibit T4 binding to albumin [<a href="#rid56">56</a>]. The same phenomenon may occur in vivo in patients with severe nonthyroidal illness who have low serum albumin concentrations (which bind free fatty acids).</p><p class="headingAnchor" id="H14"><span class="h1">OTHER CAUSES OF EUTHYROID HYPOTHYROXINEMIA</span></p><p class="headingAnchor" id="H15"><span class="h2">Antiseizure medications</span><span class="headingEndMark"> — </span>In euthyroid patients, both <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> increase nondeiodinative metabolism of T4 and T3 and displace the hormones from binding proteins. As a result, serum total and free T4 concentrations decrease by approximately 40 percent; the decrease in serum T3 is smaller, but TSH concentrations remain within the normal range [<a href="#rid57">57,58</a>]. The decrease in free T4 is an artifact in most free T4 assays. Serum free T4 is usually measured in diluted serum, and dilution of the antiseizure medication diminishes its ability to displace T4 from binding proteins. As a result, some of the free T4 becomes bound during the assay, lowering the measured value [<a href="#rid59">59</a>]. Serum free T4 (and T3) concentrations are normal when measured in undiluted serum by ultrafiltration [<a href="#rid59">59</a>]. Although less well studied, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> has also been reported to reduce total and free thyroid hormone concentrations [<a href="#rid60">60</a>].</p><p>Thus, the thyroid status in patients treated with <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> who have normal pituitary function should be assessed by measuring serum TSH alone. Hypothyroid patients treated with T4 may need an increase in dose after phenytoin or carbamazepine treatment is initiated [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Oral T3 administration</span><span class="headingEndMark"> — </span>T3 is not recommended for thyroid hormone treatment in hypothyroidism (see  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>). It is, however, used by some psychiatrists as adjunctive therapy in patients with depression who respond poorly to tricyclic antidepressant drug therapy [<a href="#rid62">62</a>]. Exogenous T3 suppresses pituitary TSH production and therefore thyroidal T4 synthesis and secretion. Thus, these patients have low serum T4, normal or slightly elevated T3, and low serum TSH concentrations.</p><p class="headingAnchor" id="H6582044"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Many conditions result in euthyroid hyperthyroxinemia or hypothyroxinemia, which are characterized by increases or decreases in serum total thyroxine (T4) and triiodothyronine (T3) concentrations, associated with normal thyroid-stimulating hormone (TSH) concentrations and no symptoms or signs of thyroid dysfunction. The free T4 index may be normal or just slightly abnormal, but in some instances, it will also be increased (eg, familial dysalbuminemic hyperthyroxinemia [FDH]). Many automated direct free T4 measurements give spurious results in patients with these conditions, especially in the presence of quantitative or qualitative changes in serum albumin concentrations. Today, when most clinicians measure serum TSH as a screening test for thyroid function and most labs are using automated "direct" free T4 assays, a normal serum TSH value is usually not followed by measurement of a total serum T4. As a result, euthyroid hyper- or hypothyroxinemia may go undetected, with no harm to the patient. (See <a class="local">'Introduction'</a> above and <a class="local">'TBG excess'</a> above and <a class="local">'Familial dysalbuminemic hyperthyroxinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common cause of hyperthyroxinemia (and hypertriiodothyroninemia) is thyroxine-binding globulin (TBG) excess due to estrogens (eg, pregnancy and oral contraceptives). Other causes of TBG excess are hereditary, hepatitis, <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">perphenazine</a>, clofibrate, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, heroin, and acute intermittent porphyria. FDH and other binding protein abnormalities can cause hyperthyroxinemia. (See <a class="local">'Euthyroid hyperthyroxinemia due to binding protein abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroxinemia due to TBG deficiency is hereditary, or due to androgens, glucocorticoids, Cushing syndrome, acromegaly, nephrotic syndrome, L-asparaginase, <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>, or <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">niacin</a>. Hypothyroxinemia may also be due to displacement of hormone from binding proteins caused by salicylates, <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a>, high-dose <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, fenclofenac and mefenamic, heparin, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>. (See <a class="local">'Euthyroid hypothyroxinemia due to binding protein abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroxinemia is expected with T3 (<a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a>) treatment, which reduces serum T4 levels via negative feedback on pituitary TSH production. (See <a class="local">'Oral T3 administration'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pappa T, Ferrara AM, Refetoff S. Inherited defects of thyroxine-binding proteins. Best Pract Res Clin Endocrinol Metab 2015; 29:735.</a></li><li><a class="nounderline abstract_t">Refetoff S. Inherited thyroxine-binding globulin abnormalities in man. Endocr Rev 1989; 10:275.</a></li><li><a class="nounderline abstract_t">Ain KB, Refetoff S. Relationship of oligosaccharide modification to the cause of serum thyroxine-binding globulin excess. J Clin Endocrinol Metab 1988; 66:1037.</a></li><li><a class="nounderline abstract_t">DOWLING JT, FREINKEL N, INGBAR SH. Thyroxine-binding by sera of pregnant women, newborn infants, and women with spontaneous abortion. J Clin Invest 1956; 35:1263.</a></li><li><a class="nounderline abstract_t">Swanson MA, Custer TR, Suey CM. Free thyroxine and free thyroxine index in women taking oral contraceptives. Clin Nucl Med 1981; 6:168.</a></li><li><a class="nounderline abstract_t">Steingold KA, Matt DW, DeZiegler D, et al. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991; 73:275.</a></li><li><a class="nounderline abstract_t">Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995; 13:854.</a></li><li><a class="nounderline abstract_t">Duntas LH, Mantzou E, Koutras DA. Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status. Thyroid 2001; 11:779.</a></li><li><a class="nounderline abstract_t">Schussler GC, Schaffner F, Korn F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med 1978; 299:510.</a></li><li><a class="nounderline abstract_t">Ross DS, Daniels GH, Dienstag JL, Ridgway EC. Elevated thyroxine levels due to increased thyroxine-binding globulin in acute hepatitis. Am J Med 1983; 74:564.</a></li><li><a class="nounderline abstract_t">Beex LV, Ross A, Smals AG, Kloppenborg PW. Letter: 5-fluorouracil and the thyroid. Lancet 1976; 1:866.</a></li><li><a class="nounderline abstract_t">McKerron CG, Scott RL, Asper SP, Levy RI. Effects of clofibrate (Atromid S) on the thyroxine-binding capacity of thyroxine-binding globulin and free thyroxine. J Clin Endocrinol Metab 1969; 29:957.</a></li><li><a class="nounderline abstract_t">Azizi F, Vagenakis AG, Portnay GI, et al. Thyroxine transport and metabolism in methadone and heroin addicts. Ann Intern Med 1974; 80:194.</a></li><li><a class="nounderline abstract_t">Hollander CS, Scott RL, Tschudy DP, et al. Increased protein-bound iodine and thyroxine-binding globulin in acute intermittent porphyria. N Engl J Med 1967; 277:995.</a></li><li><a class="nounderline abstract_t">Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2009; 200:260.e1.</a></li><li><a class="nounderline abstract_t">Arevalo G. Prevalence of familial dysalbuminemic hyperthyroxinemia in serum samples received for thyroid testing. Clin Chem 1991; 37:1430.</a></li><li><a class="nounderline abstract_t">Ruiz M, Rajatanavin R, Young RA, et al. Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis. N Engl J Med 1982; 306:635.</a></li><li><a class="nounderline abstract_t">Cartwright D, O'Shea P, Rajanayagam O, et al. Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge. Clin Chem 2009; 55:1044.</a></li><li><a class="nounderline abstract_t">Khoo S, Lyons G, McGowan A, et al. Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods. Eur J Endocrinol 2020; 182:533.</a></li><li><a class="nounderline abstract_t">Lai S, Gopalakrishnan G, Li J, et al. Familial Dysalbuminemic Hyperthyroxinemia (FDH), Albumin Gene Variant (R218S), and Risk of Miscarriages in Offspring. Am J Med Sci 2020; 360:566.</a></li><li><a class="nounderline abstract_t">Wada N, Chiba H, Shimizu C, et al. A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a Japanese kindred. J Clin Endocrinol Metab 1997; 82:3246.</a></li><li><a class="nounderline abstract_t">Nagano H, Nakagawa Y, Ishikawa N, et al. SEVEN FAMILIAL DYSALBUMINEMIC HYPERTHYROXINEMIA CASES IN THREE UNRELATED JAPANESE FAMILIES AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS OF THE THYROXINE BINDING PROFILE. Endocr Pract 2017; 23:1325.</a></li><li><a class="nounderline abstract_t">Moran C, Seger C, Taylor K, et al. Hyperthyroxinemia and Hypercortisolemia due to Familial Dysalbuminemia. Thyroid 2020; 30:1681.</a></li><li><a class="nounderline abstract_t">Moses AC, Lawlor J, Haddow J, Jackson IM. Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin. N Engl J Med 1982; 306:966.</a></li><li><a class="nounderline abstract_t">Stockigt JR, Dyer SA, Mohr VS, et al. Specific methods to identify plasma binding abnormalities in euthyroid hyperthyroxinemia. J Clin Endocrinol Metab 1986; 62:230.</a></li><li><a class="nounderline abstract_t">John R, Henley R, Shankland D. Concentrations of free thyroxin and free triiodothyronine in serum of patients with thyroxin- and triiodothyronine-binding autoantibodies. Clin Chem 1990; 36:470.</a></li><li><a class="nounderline abstract_t">Hisaoka T, Iino S, Saitoh H, et al. [Studies on patients with a discrepancy between free thyroid hormones and thyrotropin values]. Nihon Naibunpi Gakkai Zasshi 1994; 70:563.</a></li><li><a class="nounderline abstract_t">Srichomkwun P, Scherberg NH, Jakšić J, Refetoff S. Diagnostic Dilemma in Discordant Thyroid Function Tests Due to Thyroid Hormone Autoantibodies. AACE Clin Case Rep 2017; 3:e22.</a></li><li><a class="nounderline abstract_t">Figge HL, Figge J. The effects of amiodarone on thyroid hormone function: a review of the physiology and clinical manifestations. J Clin Pharmacol 1990; 30:588.</a></li><li><a class="nounderline abstract_t">Cooper DS, Daniels GH, Ladenson PW, Ridgway EC. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med 1982; 73:867.</a></li><li><a class="nounderline abstract_t">Wu SY, Chopra IJ, Solomon DH, Bennett LR. Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. J Clin Endocrinol Metab 1978; 46:691.</a></li><li><a class="nounderline abstract_t">Suzuki H, Noguchi K, Nakahata M, et al. Effect of Iopanoic acid on the pituitary-thyroid axis: time sequence of changes in serum iodothyronines, thyrotropin, and prolactin concentrations and responses to thyroid hormones. J Clin Endocrinol Metab 1981; 53:779.</a></li><li><a class="nounderline abstract_t">Kwok JS, Chan IH, Chan MH. Biotin interference on TSH and free thyroid hormone measurement. Pathology 2012; 44:278.</a></li><li><a class="nounderline abstract_t">Spratt DI, Pont A, Miller MB, et al. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73:41.</a></li><li><a class="nounderline abstract_t">Gavin LA, Rosenthal M, Cavalieri RR. The diagnostic dilemma of isolated hyperthyroxinemia in acute illness. JAMA 1979; 242:251.</a></li><li><a class="nounderline abstract_t">Styra R, Joffe R, Singer W. Hyperthyroxinemia in major affective disorders. Acta Psychiatr Scand 1991; 83:61.</a></li><li><a class="nounderline abstract_t">Mordes JP, Blume FD, Boyer S, et al. High-altitude pituitary-thyroid dysfunction on Mount Everest. N Engl J Med 1983; 308:1135.</a></li><li><a class="nounderline abstract_t">Morley JE, Shafer RB, Elson MK, et al. Amphetamine-induced hyperthyroxinemia. Ann Intern Med 1980; 93:707.</a></li><li><a class="nounderline abstract_t">Cogan E, Abramow M. Transient hyperthyroxinemia in symptomatic hyponatremic patients. Arch Intern Med 1986; 146:545.</a></li><li><a class="nounderline abstract_t">Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316:764.</a></li><li><a class="nounderline abstract_t">Sunthornthepvarakul T, Likitmaskul S, Ngowngarmratana S, et al. Familial dysalbuminemic hypertriiodothyroninemia: a new, dominantly inherited albumin defect. J Clin Endocrinol Metab 1998; 83:1448.</a></li><li><a class="nounderline abstract_t">Pan Q, Zhang Y, Zhang W, et al. The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics. Endocr Pract 2021; 27:236.</a></li><li><a class="nounderline abstract_t">Inagaki A, Miura Y, Mori Y, et al. Gene screening of thyroxine-binding globulin (TBG) deficiencies in the Japanese: only two mutations account for TBG deficiencies in the Japanese. J Clin Endocrinol Metab 1996; 81:580.</a></li><li><a class="nounderline abstract_t">Ueta Y, Mitani Y, Yoshida A, et al. A novel mutation causing complete deficiency of thyroxine binding globulin. Clin Endocrinol (Oxf) 1997; 47:1.</a></li><li><a class="nounderline abstract_t">Kobayashi H, Sakurai A, Katai M, Hashizume K. Autosomally transmitted low concentration of thyroxine-binding globulin. Thyroid 1999; 9:159.</a></li><li><a class="nounderline abstract_t">Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med 1994; 121:247.</a></li><li><a class="nounderline abstract_t">Oppenheimer JH, Werner SC. Effect of prednisone on thyroxine-binding proteins. J Clin Endocrinol Metab 1966; 26:715.</a></li><li><a class="nounderline abstract_t">Kaplan MM. Clinical and laboratory assessment of thyroid abnormalities. Med Clin North Am 1985; 69:863.</a></li><li><a class="nounderline abstract_t">Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol 1982; 2:70.</a></li><li><a class="nounderline abstract_t">Garnick MB, Larsen PR. Acute deficiency of thyroxine-binding globulin during L-asparaginase therapy. N Engl J Med 1979; 301:252.</a></li><li><a class="nounderline abstract_t">Graham RL, Gambrell RD Jr. Changes in thyroid function tests during danazol therapy. Obstet Gynecol 1980; 55:395.</a></li><li><a class="nounderline abstract_t">Shakir KM, Kroll S, Aprill BS, et al. Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state. Mayo Clin Proc 1995; 70:556.</a></li><li><a class="nounderline abstract_t">Faber J, Waetjen I, Siersbaek-Nielsen K. Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin. Clin Chim Acta 1993; 223:159.</a></li><li><a class="nounderline abstract_t">McConnell RJ. Abnormal thyroid function test results in patients taking salsalate. JAMA 1992; 267:1242.</a></li><li><a class="nounderline abstract_t">Stockigt JR, Lim CF, Barlow JW, et al. Interaction of furosemide with serum thyroxine-binding sites: in vivo and in vitro studies and comparison with other inhibitors. J Clin Endocrinol Metab 1985; 60:1025.</a></li><li><a class="nounderline abstract_t">Mendel CM, Frost PH, Kunitake ST, Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 1987; 65:1259.</a></li><li><a class="nounderline abstract_t">Smith PJ, Surks MI. Multiple effects of 5,5'-diphenylhydantoin on the thyroid hormone system. Endocr Rev 1984; 5:514.</a></li><li><a class="nounderline abstract_t">Isojärvi JI, Pakarinen AJ, Myllylä VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989; 46:1175.</a></li><li><a class="nounderline abstract_t">Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA 1996; 275:1495.</a></li><li><a class="nounderline abstract_t">Isojärvi JI, Turkka J, Pakarinen AJ, et al. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001; 42:930.</a></li><li><a class="nounderline abstract_t">Blackshear JL, Schultz AL, Napier JS, Stuart DD. Thyroxine replacement requirements in hypothyroid patients receiving phenytoin. Ann Intern Med 1983; 99:341.</a></li><li><a class="nounderline abstract_t">Jackson IM. Does thyroid hormone have a role as adjunctive therapy in depression? Thyroid 1996; 6:63.</a></li></ol></div><div id="topicVersionRevision">Topic 7892 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26522458" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inherited defects of thyroxine-binding proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2506004" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inherited thyroxine-binding globulin abnormalities in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3129446" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relationship of oligosaccharide modification to the cause of serum thyroxine-binding globulin excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13376719" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyroxine-binding by sera of pregnant women, newborn infants, and women with spontaneous abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7214772" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Free thyroxine and free thyroxine index in women taking oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906893" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707111" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525272" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/98709" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6404165" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Elevated thyroxine levels due to increased thyroxine-binding globulin in acute hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/56692" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Letter: 5-fluorouracil and the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4978385" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of clofibrate (Atromid S) on the thyroxine-binding capacity of thyroxine-binding globulin and free thyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4204545" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thyroxine transport and metabolism in methadone and heroin addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4168454" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Increased protein-bound iodine and thyroxine-binding globulin in acute intermittent porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114271" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Free T4 immunoassays are flawed during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1868606" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of familial dysalbuminemic hyperthyroxinemia in serum samples received for thyroid testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6173750" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282355" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213658" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32665066" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial Dysalbuminemic Hyperthyroxinemia (FDH), Albumin Gene Variant (R218S), and Risk of Miscarriages in Offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329347" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a Japanese kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28816534" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : SEVEN FAMILIAL DYSALBUMINEMIC HYPERTHYROXINEMIA CASES IN THREE UNRELATED JAPANESE FAMILIES AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS OF THE THYROXINE BINDING PROFILE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32669045" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyperthyroxinemia and Hypercortisolemia due to Familial Dysalbuminemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6801514" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079602" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Specific methods to identify plasma binding abnormalities in euthyroid hyperthyroxinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2311215" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Concentrations of free thyroxin and free triiodothyronine in serum of patients with thyroxin- and triiodothyronine-binding autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7958106" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : [Studies on patients with a discrepancy between free thyroid hormones and thyrotropin values].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28078322" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diagnostic Dilemma in Discordant Thyroid Function Tests Due to Thyroid Hormone Autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202751" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effects of amiodarone on thyroid hormone function: a review of the physiology and clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6816067" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hyperthyroxinemia in patients treated with high-dose propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/582597" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6793610" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of Iopanoic acid on the pituitary-thyroid axis: time sequence of changes in serum iodothyronines, thyrotropin, and prolactin concentrations and responses to thyroid hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22437752" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Biotin interference on TSH and free thyroid hormone measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807087" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hyperthyroxinemia in patients with acute psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/448913" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The diagnostic dilemma of isolated hyperthyroxinemia in acute illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2011957" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hyperthyroxinemia in major affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6835338" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High-altitude pituitary-thyroid dysfunction on Mount Everest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6782925" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Amphetamine-induced hyperthyroxinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954527" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transient hyperthyroxinemia in symptomatic hyponatremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3821822" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589637" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Familial dysalbuminemic hypertriiodothyroninemia: a new, dominantly inherited albumin defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779557" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636271" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Gene screening of thyroxine-binding globulin (TBG) deficiencies in the Japanese: only two mutations account for TBG deficiencies in the Japanese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302363" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A novel mutation causing complete deficiency of thyroxine binding globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090316" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Autosomally transmitted low concentration of thyroxine-binding globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7518657" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4161988" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of prednisone on thyroxine-binding proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3903380" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and laboratory assessment of thyroid abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7180903" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Thyroid function in patients with nephrotic syndrome and normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/109764" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute deficiency of thyroxine-binding globulin during L-asparaginase therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7360440" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Changes in thyroid function tests during danazol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776715" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143362" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538562" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Abnormal thyroid function test results in patients taking salsalate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2579968" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Interaction of furosemide with serum thyroxine-binding sites: in vivo and in vitro studies and comparison with other inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3680482" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6094173" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Multiple effects of 5,5'-diphenylhydantoin on the thyroid hormone system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2510703" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Thyroid function in epileptic patients treated with carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622224" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488894" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614682" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Thyroxine replacement requirements in hypothyroid patients receiving phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8777387" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Does thyroid hormone have a role as adjunctive therapy in depression?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
